Endocrine Drugs

Endocrine therapeutics span obesity, diabetes, thyroid and bone health with the GLP-1 era expanding indications. The session covers GLP-1 multi-agonists (retatrutide, mazdutide), oral PCSK9 (MK-0616 enlicitide), finerenone across CKD and HF, sotatercept (Winrevair) beyond PAH (AKAR-7 in HF), romosozumab (Evenity) in osteoporosis, and selective glucocorticoid receptor modulators. Discussion addresses thyroid hormone analogues (resmetirom), GnRH antagonists in fibroids and endometriosis, sodium-glucose linked transporter inhibitors, parathyroid hormone derivatives, and the integration with cardiometabolic risk reduction.